Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erbitux and Reirradiation in Recurrent Head and Neck Cancer
NCT01237483Phase 2Completed
- Sponsor
- GORTEC
- Start
- Oct 2010
- Primary completion
- Jul 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by GORTEC. Started Oct 2010; status: completed.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01237483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01237483.